Skip to main content

Table 2 Mean PRO scores corresponding to PASDAS and ScoreMDA cutoffs for disease activity

From: Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

PRO*

Mean scores (95% CI) corresponding to PASDAS cutoffs for disease activity

Mean scores (95% CI) corresponding to MDA

Very low: 1.9

Low: 3.2

High: 5.4

5 points

EQ-5D-3L VAS

 OPAL Broaden

78.2 (76.6, 79.8)

69.5 (68.2, 70.7)

54.7 (53.4, 56.0)

74.6 (73.0, 76.2)

 OPAL Beyond

78.9 (76.7, 81.1)

69.9 (68.2, 71.6)

54.7 (53.2, 56.1)

75.5 (73.2, 77.9)

EQ-5D-3L UI

 OPAL Broaden

0.8 (0.8, 0.8)

0.7 (0.7, 0.7)

0.5 (0.5, 0.6)

0.8 (0.7, 0.8)

 OPAL Beyond

0.8 (0.8, 0.8)

0.7 (0.7, 0.7)

0.5 (0.5, 0.5)

0.8 (0.7, 0.8)

FACIT-F total score

 OPAL Broaden

40.1 (39.2, 41.0)

36.4 (35.6, 37.2)

30.2 (29.4, 31.0)

38.2 (37.3, 39.1)

 OPAL Beyond

40.6 (39.5, 41.7)

36.3 (35.3, 37.2)

29.0 (28.1, 29.8)

39.2 (38.0, 40.4)

FACIT-F ED

 OPAL Broaden

14.3 (14.0, 14.7)

12.7 (12.3, 13.0)

9.9 (9.6, 10.2)

13.4 (13.0, 13.8)

 OPAL Beyond

14.4 (13.9, 15.0)

12.6 (12.2, 13.0)

9.4 (9.0, 9.8)

13.9 (13.4, 14.4)

FACIT-F ID

 OPAL Broaden

25.8 (25.2, 26.3)

23.7 (23.2, 24.2)

20.3 (19.8, 20.8)

24.9 (24.3, 25.4)

 OPAL Beyond

26.2 (25.5, 26.9)

23.7 (23.1, 24.3)

19.6 (19.0, 20.1)

25.4 (24.7, 26.1)

PGJS-VAS, mm

 OPAL Broaden

12.6 (11.1, 14.0)

28.2 (27.1, 29.3)

54.7 (53.6, 55.8)

22.1 (20.4, 23.7)

 OPAL Beyond

11.4 (9.5, 13.3)

27.8 (26.3, 29.2)

55.4 (54.1, 56.7)

20.2 (17.7, 22.7)

PGJS-VAS-PsO, mm

 OPAL Broaden

11.0 (9.1, 12.9)

24.0 (22.4, 25.5)

45.9 (44.2, 47.5)

18.7 (16.7, 20.6)

 OPAL Beyond

8.6 (6.0, 11.2)

22.2 (20.2, 24.2)

45.2 (43.3, 47.0)

16.5 (13.6, 19.5)

SF-36v2 PCS

 OPAL Broaden

NA

NA

NA

45.2 (44.5, 45.8)

 OPAL Beyond

NA

NA

NA

44.6 (43.7, 45.5)

SF-36v2 PF

 OPAL Broaden

NA

NA

NA

45.3 (44.5, 46.1)

 OPAL Beyond

NA

NA

NA

43.4 (42.3, 44.5)

Pain VAS

 OPAL Broaden

13.4 (11.8, 15.0)

26.3 (25.0, 27.5)

48.0 (46.7, 49.4)

NA

 OPAL Beyond

11.5 (9.3, 13.8)

25.4 (23.7, 27.1)

48.8 (47.4, 50.3)

NA

HAQ-DI

 OPAL Broaden

0.5 (0.4, 0.5)

0.7 (0.6, 0.7)

1.0 (1.0, 1.0)

NA

 OPAL Beyond

0.5 (0.4, 0.6)

0.7 (0.7, 0.8)

1.2 (1.1, 1.2)

NA

  1. SF-36v2 PCS: norm-based scores were used (a score of 50 representing the mean for the general population, with higher scores indicating less impairment); ScoreMDA: continuous MDA with values from 0 to 7 (0–4, no MDA; 5–7, MDA)
  2. CI confidence interval, ED experience domain, EQ-5D-3L EuroQoL-Five Dimensions-Three Level Health Questionnaire, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, ID impact domain, MDA minimal disease activity, NA not assessed, Pain VAS Patient’s Assessment of Arthritis Pain visual analog scale, PASDAS Psoriatic Arthritis Disease Activity Score, PCS Physical Component Summary, PF physical functioning, PGJS-VAS Patient’s Global Joint and Skin Assessment visual analog scale, PGJS-VAS-PsO PGJS-VAS psoriasis question, PRO patient-reported outcome, SF-36v2 Short Form-36 Health Survey Version 2, acute, VAS visual analog scale
  3. *OPAL Broaden, N = 422; OPAL Beyond, N = 394; all treatment groups from each phase 3 study were pooled for analysis